Dare Bioscience (DARE) Operating Expenses (2013 - 2026)
Dare Bioscience's (DARE) quarterly Operating Expenses came in at $2.2 million in Q4 2025, down 58.7% YoY from $5.3 million in Q4 2024, and down 40.15% on a QoQ basis from $3.7 million in Q3 2025.
Dare Bioscience (DARE) Operating Expenses (2013 - 2026) Analysis & Trends
Dare Bioscience (DARE) has 13 years of Operating Expenses data on file, last reported at $2.2 million in Q4 2025.
- Quarterly Operating Expenses fell 58.7% year-over-year to $2.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $14.3 million (down 39.11% YoY) and the FY2025 annual result came in at $14.3 million, down 39.11% from the prior year.
- Operating Expenses declined to $2.2 million in Q4 2025, from $3.7 million in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $16.2 million in Q4 2022 to a low of $2.2 million in Q4 2025.
- A 5-year average of $7.6 million and a median of $7.5 million in 2021 frame the typical range for Operating Expenses.
- Annual changes were most pronounced in 2021 — Operating Expenses jumped 80.85% — and 2025, when it slumped 58.7%.
- Tracing DARE's Operating Expenses over 5 years: stood at $9.5 million in 2021, then jumped by 70.08% to $16.2 million in 2022, then tumbled by 57.0% to $7.0 million in 2023, then declined by 23.71% to $5.3 million in 2024, then tumbled by 58.7% to $2.2 million in 2025.
- The last three Operating Expenses figures came in at $2.2 million (Q4 2025), $3.7 million (Q3 2025), and $3.8 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.06 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -784.57 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 427.03 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 541.02 Mn |
| 10 | Dare Bioscience | 12.36 Mn | -256,055.23 | -132,343.00 | 2.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.84 Mn |
| Dec 31, 2025 | 2.20 Mn |
| Sep 30, 2025 | 3.67 Mn |
| Jun 30, 2025 | 3.81 Mn |
| Mar 31, 2025 | 4.61 Mn |
| Dec 31, 2024 | 5.32 Mn |
| Sep 30, 2024 | 4.72 Mn |
| Jun 30, 2024 | 7.38 Mn |
| Mar 31, 2024 | 6.03 Mn |
| Dec 31, 2023 | 6.98 Mn |
| Sep 30, 2023 | 9.40 Mn |
| Jun 30, 2023 | 8.99 Mn |
| Mar 31, 2023 | 8.38 Mn |
| Dec 31, 2022 | 16.23 Mn |
| Sep 30, 2022 | 7.14 Mn |
| Jun 30, 2022 | 9.62 Mn |
| Mar 31, 2022 | 8.40 Mn |
| Dec 31, 2021 | 9.54 Mn |
| Sep 30, 2021 | 12.67 Mn |
| Jun 30, 2021 | 9.16 Mn |